Based on panel consensus, the following regimens have been added as category 2A recommendations for management of CHL in older adults (age >60 y):

**Stage I-II Favorable Disease:**
- ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
- AVD (doxorubicin, vinblastine, and dacarbazine)
- CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
- VEPEMB (vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone, and bleomycin)

**Stage I-II Unfavorable/ Stage III-IV Disease**
- ABVD
- AVD
- CHOP
- PVAG (prednisone, vinblastine, doxorubicin, and gemcitabine)
- VEPEMB

**Palliative therapy only**
- Bendamustine
- Brentuximab vedotin
- Everolimus
- Lenalidomide
- Nivolumab
- Pembrolizumab

See the section on “Management of classical Hodgkin lymphoma in older adults (age >60 y)” in the NCCN Guidelines for Hodgkin Lymphoma for references.